TITLE

Bill Provision Would Eliminate FDA Panel Conflicts

PUB. DATE
October 2007
SOURCE
HealthLeaders Magazine;Oct2007, Vol. 10 Issue 10, p19
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses a provision in the 2008 agricultural appropriations bill approved by the U.S. House of Representatives that requires the Food & Drug Administration (FDA) to eliminate conflicts of interests on its advisory committees. The provision prohibits experts who have more than US$50,000 interest in pharmaceutical companies from serving in panels that review their products but allows those with less, to participate in committee discussions but could not vote on recommending products.
ACCESSION #
27654644

 

Related Articles

  • Experts on the Take. Mokhiber, Russell // Multinational Monitor;Nov2000, Vol. 21 Issue 11, p29 

    Reveals that experts hired by the United States Food and Drug Administration have financial relationships with pharmaceutical companies. Percentage of experts with financial interest in the pharmacy industry or in topic they are asked to evaluate; Implications of their interests to the health...

  • FDA Seeks to Revamp Panels. Agres, Ted // Drug Discovery & Development;Aug2006, Vol. 9 Issue 8, p6 

    The article reports on the plan of the U.S. Food and Drug Administration to reassess how it selects and uses advisory committee members having potential financial conflicts of interest with pharmaceutical companies. FDA plans to hold a public hearing as a prelude to updating guidance on how it...

  • NIH, FDA Conflicts of Interest May Threaten R&D. Wechsler, Jill // Pharmaceutical Executive;Jul2004, Vol. 24 Issue 7, p24 

    Presents an update on the congressional investigation of the potential conflicts of interest between federal government employees and pharmaceutical companies in the United States. Focus on allegations of questionable payments and relationships between the two sectors; Concern that further...

  • WATCHDOGS POODLES, GUINEA PIGS AND DRUGS.  // Ecologist;Dec2006, Vol. 36 Issue 10, p12 

    This article explains that when it comes to a conflict of interest, it is hard to beat that which exists between the global pharmaceutical corporations and the U.S. drug watchdog. Regulators usually do not negotiate their budgets with the industries they oversee… but the U.S. Food and Drug...

  • FDA tightens advisory group criteria. J. G. D. // Medical Marketing & Media;May2007, Vol. 42 Issue 5, p14 

    The article reports on the disqualification of current advisory committee members of the U.S. Food and Drug Administration (FDA) from participating in future panel deliberations under new guidelines proposed in an agency draft guidance document. According to the FDA, it does not have an exact...

  • Will paranoia kill research? Ross, Warren // Medical Marketing & Media;Apr2005, Vol. 40 Issue 4, p78 

    Comments on the manifestation of conflict of interest in the U.S. Food and Drug Administration (FDA). Connection of the ten of the 32 members of the FDA advisory panel who voted to keep Bextra and Celebrex to the market to the pharmaceutical industry; Restriction of consulting arrangements...

  • FDA is criticised for hinting at looser conflict of interest rules. Lenzer, Jeanne // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/13/2011, Vol. 343 Issue 7819, p338 

    No abstract available.

  • Ethics group wants FDA to drop two tobacco panel advisers over 'conflicts'. Pecquet, Julian // Hill;6/8/2010, Vol. 17 Issue 63, p18 

    The article reports that good-government group Citizens for Responsibility and Ethics in Washington is urging the U.S. Food and Drug Administration to dismiss two members of its advisory panel on tobacco products for financial conflicts of interests.

  • Conflicts of Interest Among Patient and Consumer Representatives to U.S. Food and Drug Administration Drug Advisory Committees. Graham, S. Scott; Card, Daniel J.; Seokhoon Ahn; Sang-Yeon Kim; Kessler, Molly M.; Olson, Michelle K.; Ahn, Seokhoon; Kim, Sang-Yeon // Annals of Internal Medicine;10/18/2016, Vol. 165 Issue 8, p606 

    A letter to the editor is presented in response to the article "Measuring conflict of interest and expertise on FDA advisory committees" by N. Ackerly in the December 10, 2013 issue.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics